Promore Pharma
9.11.2021 12:02:15 CET | ACCESS Newswire | Press release
STOCKHOLM, SE / ACCESSWIRE / November 9, 2021 / Promore Pharma (STO:PROMO)(FRA:8T0)
Stockholm, November 9, 2021 - Promore Pharma AB, a Swedish biopharmaceutical company that develops peptide-based drug candidates, announced today that the company has received approval from the Medical Products Agency and the Swedish Ethics Review Authority to begin a clinical phase II trial of ensereptide for skin scarring prevention.
The company announces today that a clinical trial permit has been obtained from the Medical Products Agency in Sweden and that the company's application for approval from the Ethical Review Authority has also been granted. PHSU05 is a Phase II pilot study with the aim of being able to evaluate ensereptide regarding (i) local tolerance, (ii) the application process of the experimental drug, and (iii) preliminary effect on scar prevention after experimentally induced wounds in healthy volunteers. Planned study start is Q1 2022 and results from the study are expected in the winter of 2022/2023.
"This is an important step in our long-term goal of developing a new product concept to prevent the occurrence of post-surgical and post-traumatic scars on the skin. These approvals are fully aligned with our operational plan in the ensereptide project ", says Jonas Ekblom, CEO of Promore Pharma.
Bolagets ensereptide-program fokuseras för närvarande på prevention av ärr i huden i samband med kirurgi eller trauma, men det finns även potential att utveckla produkten för andra medicinska applikationer som prevention av sammanväxning efter hand- och ryggradskirurgi.
The company's ensereptide program is currently focused on the prevention of scarring of the skin in connection with surgery or trauma, but there is also potential to develop the product for other medical applications such as prevention of adhesions after surgeries in the hand or spine.
Scars develop after virtually all types of damage to the skin. Although scars can often be considered trivial, a large proportion of them can be disfiguring and aesthetically pleasing, and they can also create itching, stiffness, sleep problems, anxiety, depression and negatively affect activities of daily life.
The world market for products for the treatment of scars, including laser treatment, scar revision and self-care products, amounts to USD 25 billion with an annual growth of about 10%, according to independent estimates. Today, there are no prescription drugs for wound prevention.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
This information is information that Promore Pharma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-11-09 11:38 CET.
Attachments
Promore Pharma receives permits to start a phase II clinical trial regarding scar prevention
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/671849/Promore-Pharma-Receives-Permits-to-Start-a-Phase-II-Clinical-Trial-Regarding-Scar-Prevention
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
U.S. Air Force Awards GA-ASI Production Contract for FQ-42A CCA18.6.2026 00:10:00 CEST | Press release
Company Will Produce Service's New Uncrewed Combat Jets SAN DIEGO, CA / ACCESS Newswire / June 17, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) has received a production contract from the U.S. Air Force (USAF) for the FQ-42A Collaborative Combat Aircraft (CCA). The initial order is a significant milestone, beginning the delivery of production aircraft to the warfighter. GA-ASI designed, developed and flight-tested FQ-42A on an accelerated schedule unlike any fighter in recent history. "This is an exciting day for our company and the nation," said company President David R. Alexander. "Moving to production on FQ-42A is the result of an extraordinary partnership and many years of investments between General Atomics and the U.S. Air Force. We've been preparing for this order, and manufacturing is already well underway." The FQ-42A is a purpose-built, uncrewed fighter developed as part of ongoing investment in next-generation semi-autonomous combat aircraft. The aircraft's mo
Polaris Renewable Energy Announces Postponement of Annual Meeting of Shareholders17.6.2026 23:30:00 CEST | Press release
TORONTO, ON / ACCESS Newswire / June 17, 2026 / Polaris Renewable Energy Inc. (the "Corporation" or "Polaris") today announced that its annual meeting of shareholders (the "Meeting"), originally scheduled to be held on June 18, 2026 at 9:00 a.m. (Toronto time), has been postponed. The Meeting will now be held as follows: Date: June 26, 2026 Time: 9:00 a.m. (Toronto time) Format: Virtual-only meeting Webcast: https://virtual-meetings.tsxtrust.com/1923 Password: "polaris2026" The Meeting will be conducted in the same virtual format as previously announced, and shareholders will continue to be able to attend, participate and vote online through the TSX Trust virtual meeting platform. Purpose of Postponement The postponement is being done as the required quorum of 50.1% of shareholders voting has not been achieved at this point in time. We encourage shareholders that have not yet voted their shares to do so prior to 9 am on June 25th. Meeting Materials and Business The business of the Meet
Innodata Appoints Jayant Chauhan as Chief Financial Officer17.6.2026 22:30:00 CEST | Press release
Brings More Than Two Decades of Experience in Finance and Scaling High-Growth Technology Companies, Effective July 6, 2026 Interim CFO Marissa Espineli to Transition to Chief Accounting Officer NEW YORK, NY / ACCESS Newswire / June 17, 2026 / INNODATA INC. (Nasdaq:INOD) ("Innodata" or the "Company") today announced that it has appointed Jayant Chauhan as Executive Vice President and Chief Financial Officer (CFO), effective July 6, 2026. At that time, Marissa Espineli, who is serving as the Company's Interim Chief Financial Officer, will transition to the new role of Chief Accounting Officer, reporting to Mr. Chauhan. Mr. Chauhan brings to Innodata more than two decades of experience building and leading finance functions for fast-growing global technology companies. He most recently served as Senior Vice President, M&A at Mphasis, a Blackstone-owned, publicly traded global IT services company, and previously as Senior Vice President, Global Strategic Finance, and CFO of the operated ho
Qualitest Becomes QualityAI: The Trusted Assurance and Engineering Partner Across Every Stage of Enterprise AI17.6.2026 18:45:00 CEST | Press release
As businesses double down on AI deployment, QualityAI helps enterprise leaders move beyond AI claims and go live with confidence. LONDON, UK / ACCESS Newswire / June 17, 2026 / Qualitest, the leading provider of AI-first quality engineering and assurance, today announces its rebrand to QualityAI. The new brand reflects the company's evolution from software testing specialist to AI-first quality engineering partner, helping enterprises design quality into complex systems from the outset. Across every industry, companies are racing to adopt AI, and the pressure to demonstrate progress is rising. According to Deloitte's 2026 "State of AI in the Enterprise" report, the proportion of organizations expecting at least 40% of AI experiments to reach production is expected to more than double within six months. As AI moves from ambition to implementation, leaders need to prove that transformation is real, reliable, and effective. In a market crowded with AI claims, assurance is becoming the dif
Skymantics Europe Joins BDVA to Overcome Data Scarcity Barriers in European AI Adoption17.6.2026 14:35:00 CEST | Press release
Providing fully GDPR-compliant synthetic population datasets to unlock paralyzed AI initiatives in Europe. ZARAGOZA, ES / ACCESS Newswire / June 17, 2026 / Skymantics Europe, developer of the DataGenesis™ AI software, today announced it has joined the Big Data Value Association (BDVA). This membership marks a pivotal step in Skymantics Europe's mission to help overcome one of the major barriers to European AI adoption, namely "data scarcity": availability of large quantities of high-quality data, compliant with GDPR and European AI Act. As European governments and businesses accelerate the AI adoption for complex decision-support environments, they face a recurring "Compliance Paradox": the need for high-fidelity data to drive innovation versus the legal requirement to protect citizen privacy. Skymantics Europe resolves this tension via DataGenesis™, its proprietary software engine that generates behavioral digital twins mathematically indistinguishable from production datasets, yet co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom